These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38493020)

  • 21. Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    Powell CB; Laurent C; Ciaravino G; Garcia C; Han L; Hoodfar E; Karlea A; Kobelka C; Lee J; Littell RD; Roh J; Vay A; Kushi LH
    Gynecol Oncol; 2020 Oct; 159(1):221-228. PubMed ID: 32778409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014.
    Wu SG; Li FY; Lei J; Hua L; He ZY; Zhou J
    Med Sci Monit; 2020 Feb; 26():e920531. PubMed ID: 32008036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
    Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
    BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    Tone AA; McCuaig JM; Ricker N; Boghosian T; Romagnuolo T; Stickle N; Virtanen C; Zhang T; Kim RH; Ferguson SE; May T; Laframboise S; Armel S; Demsky R; Volenik A; Stuart-McEwan T; Shaw P; Oza A; Kamel-Reid S; Stockley T; Bernardini MQ
    Gynecol Oncol; 2021 Jul; 162(1):97-106. PubMed ID: 33858678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.
    Bednar EM; Sun CC; Camacho B; Terrell J; Rieber AG; Ramondetta LM; Freedman RS; Lu KH
    Gynecol Oncol; 2019 Feb; 152(2):328-333. PubMed ID: 30528888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.
    Hlaváč V; Holý P; Václavíková R; Rob L; Hruda M; Mrhalová M; Černaj P; Bouda J; Souček P
    Life Sci Alliance; 2022 Oct; 5(12):. PubMed ID: 36229065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study.
    Sobocan M; Chandrasekaran D; Sideris M; Blyuss O; Fierheller C; Kalra A; Sia J; Miller RE; Mills-Baldock T; Crusz SM; Sun L; Evans O; Robbani S; Jenkins LA; Ahmed M; Kumar A; Quigley M; Lockley M; Faruqi A; Casey L; Brockbank E; Phadnis S; Trevisan G; Singh N; Legood R; Manchanda R
    BJOG; 2024 May; 131(6):848-857. PubMed ID: 37752678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer.
    Ip E; Young AL; Scheinberg T; Harrison M; Beale P; Goodwin A
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e414-e419. PubMed ID: 35098668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
    McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
    Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
    Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
    Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are Detailed, Patient-level Social Determinant of Health Factors Associated With Physical Function and Mental Health at Presentation Among New Patients With Orthopaedic Conditions?
    Bernstein DN; Lans A; Karhade AV; Heng M; Poolman RW; Schwab JH; Tobert DG
    Clin Orthop Relat Res; 2023 May; 481(5):912-921. PubMed ID: 36201422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
    Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
    Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
    J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of stage III mucinous and serous ovarian cancer: a case-control study.
    Firat Cuylan Z; Karabuk E; Oz M; Turan AT; Meydanli MM; Taskin S; Sari ME; Sahin H; Ulukent SC; Akbayir O; Gungorduk K; Gungor T; Kose MF; Ayhan A
    J Ovarian Res; 2018 Oct; 11(1):91. PubMed ID: 30376858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.
    van de Vorst REWM; Hoogendam JP; van der Aa MA; Witteveen PO; Zweemer RP; Gerestein CG
    Gynecol Oncol; 2021 Jun; 161(3):876-883. PubMed ID: 33849726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
    Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Filippova OT; Tin AL; Alonso J; Vickers AJ; Tew WP; Gardner GJ; Sonoda Y; Roche KL; Zivanovic O; Chi DS; Shahrokni A
    Gynecol Oncol; 2021 Jun; 161(3):687-692. PubMed ID: 33773807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    Manrriquez E; Chapman JS; Mak J; Blanco AM; Chen LM
    Gynecol Oncol; 2018 Apr; 149(1):84-88. PubMed ID: 29605055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    McCuaig JM; Care M; Ferguson SE; Kim RH; Stockley TL; Metcalfe KA
    Gynecol Oncol; 2020 Sep; 158(3):747-753. PubMed ID: 32674931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.